TY - JOUR
T1 - Transfection-independent production of alphavirus replicon particles based on poxvirus expression vectors
AU - Vasilakis, Nikos
AU - Falvey, Darlene
AU - Gangolli, Seema S.
AU - Coleman, John
AU - Kowalski, Jacek
AU - Udem, Stephen A.
AU - Zamb, Timothy J.
AU - Kovacs, Gerald R.
N1 - Funding Information:
1Viral Vaccine Discovery, Wyeth Vaccines Research, Pearl River, New York 10965, USA. 2Present addresses: Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, Texas 77555, USA (N.V.) and Office of Biodefense Research Affairs, National Institute of Allergy and Infectious Diseases, National Institutes of Heath, Bethesda, Maryland 20892, USA (G.R.K.). Correspondence should be addressed to G.R.K. ([email protected]).
PY - 2003/8/1
Y1 - 2003/8/1
N2 - This report describes a transfection-independent system for packaging alphavirus replicon vectors using modified vaccinia virus Ankara (MVA) vectors to express all of the RNA components necessary for the production of Venezuelan equine encephalitis (VEE) virus replicon particles (VRP). Infection of mammalian cells with these recombinant MVA vectors resulted in robust expression of VEE structural genes, replication of the alphavirus vector and high titers of VRP. In addition, VRP packaging was achieved in a cell type (fetal rhesus lung) that has been approved for the manufacturing of vaccines destined for human use.
AB - This report describes a transfection-independent system for packaging alphavirus replicon vectors using modified vaccinia virus Ankara (MVA) vectors to express all of the RNA components necessary for the production of Venezuelan equine encephalitis (VEE) virus replicon particles (VRP). Infection of mammalian cells with these recombinant MVA vectors resulted in robust expression of VEE structural genes, replication of the alphavirus vector and high titers of VRP. In addition, VRP packaging was achieved in a cell type (fetal rhesus lung) that has been approved for the manufacturing of vaccines destined for human use.
UR - http://www.scopus.com/inward/record.url?scp=0043208876&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0043208876&partnerID=8YFLogxK
U2 - 10.1038/nbt845
DO - 10.1038/nbt845
M3 - Article
C2 - 12845329
AN - SCOPUS:0043208876
SN - 1087-0156
VL - 21
SP - 932
EP - 935
JO - Nature Biotechnology
JF - Nature Biotechnology
IS - 8
ER -